{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T02:43:48Z","timestamp":1775529828619,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T00:00:00Z","timestamp":1370476800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Geriatr"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2318-13-56","type":"journal-article","created":{"date-parts":[[2013,6,6]],"date-time":"2013-06-06T16:15:10Z","timestamp":1370535310000},"source":"Crossref","is-referenced-by-count":23,"title":["Evaluating the cognitive effects of donepezil 23\u2009mg\/d in moderate and severe Alzheimer\u2019s disease: analysis of effects of baseline features on treatment response"],"prefix":"10.1186","volume":"13","author":[{"given":"Marwan","family":"Sabbagh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Cummings","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Doody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Farlow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Mackell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi","family":"Fain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,6]]},"reference":[{"key":"863_CR1","doi-asserted-by":"publisher","first-page":"773","DOI":"10.2174\/156720512802455412","volume":"9","author":"RS Doody","year":"2012","unstructured":"Doody RS, Cummings JL, Farlow MR: Reviewing the role of donepezil in the treatment of Alzheimer\u2019s disease. Curr Alzheimer Res. 2012, 9: 773-781. 10.2174\/156720512802455412.","journal-title":"Curr Alzheimer Res"},{"key":"863_CR2","first-page":"CD001190","volume":"3","author":"JS Birks","year":"2003","unstructured":"Birks JS, Harvey R: Donepezil for dementia due to Alzheimer\u2019s disease. Cochrane Database Syst Rev. 2003, 3: CD001190-","journal-title":"Cochrane Database Syst Rev"},{"key":"863_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/gps.1133","volume":"19","author":"A Whitehead","year":"2004","unstructured":"Whitehead A, Perdomo C, Pratt RD, Birks J, Wilcock GK, Evans JG: Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer\u2019s disease: a meta-analysis of individual patient data from randomised controlled trials. Int J Geriatr Psychiatry. 2004, 19: 624-633. 10.1002\/gps.1133.","journal-title":"Int J Geriatr Psychiatry"},{"key":"863_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000122961","volume":"25","author":"A Homma","year":"2008","unstructured":"Homma A, Imai Y, Tago H, Asada T, Shigeta M, Iwamoto T, Takita M, Arimoto I, Koma H, Ohbayashi T: Donepezil treatment of patients with severe Alzheimer\u2019s disease in a Japanese population: results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord. 2008, 25: 399-407. 10.1159\/000122961.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"863_CR5","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1479-8301.2009.00291.x","volume":"9","author":"M Nozawa","year":"2009","unstructured":"Nozawa M, Ichimiya Y, Nozawa E, Utumi Y, Sugiyama H, Murayama N, Iseki E, Arai H: Clinical effects of high oral dose of donepezil for patients with Alzheimer\u2019s disease in Japan. Psychogeriatrics. 2009, 9: 50-55. 10.1111\/j.1479-8301.2009.00291.x.","journal-title":"Psychogeriatrics"},{"key":"863_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/j.clinthera.2010.06.019","volume":"32","author":"MR Farlow","year":"2010","unstructured":"Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A: Effectiveness and tolerability of high-dose (23 mg\/d) versus standard-dose (10 mg\/d) donepezil in moderate to severe Alzheimer\u2019s disease: a 24-week, randomized, double-blind study. Clin Ther. 2010, 32: 1234-1251. 10.1016\/j.clinthera.2010.06.019.","journal-title":"Clin Ther"},{"key":"863_CR7","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1185\/03007990903236731","volume":"25","author":"B Winblad","year":"2009","unstructured":"Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K: Donepezil treatment in severe Alzheimer\u2019s disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009, 25: 2577-2587.","journal-title":"Curr Med Res Opin"},{"key":"863_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1002\/(SICI)1099-1166(200001)15:1<50::AID-GPS75>3.0.CO;2-M","volume":"15","author":"M Evans","year":"2000","unstructured":"Evans M, Ellis A, Watson D, Chowdhury T: Sustained cognitive improvement following treatment of Alzheimer\u2019s disease with donepezil. Int J Geriatr Psychiatry. 2000, 15: 50-53. 10.1002\/(SICI)1099-1166(200001)15:1<50::AID-GPS75>3.0.CO;2-M.","journal-title":"Int J Geriatr Psychiatry"},{"key":"863_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1136\/jnnp.2004.043539","volume":"76","author":"PJ Connelly","year":"2005","unstructured":"Connelly PJ, Prentice NP, Fowler KG: Predicting the outcome of cholinesterase inhibitor treatment in Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2005, 76: 320-324. 10.1136\/jnnp.2004.043539.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"863_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1001\/archneur.58.3.417","volume":"58","author":"MR Farlow","year":"2001","unstructured":"Farlow MR, Hake A, Messina J, Hartman R, Veach J, Anand R: Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression. Arch Neurol. 2001, 58: 417-422. 10.1001\/archneur.58.3.417.","journal-title":"Arch Neurol"},{"key":"863_CR11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000051228","volume":"11","author":"S Lilienfeld","year":"2000","unstructured":"Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer\u2019s disease. Dement Geriatr Cogn Disord. 2000, 11: 19-27. 10.1159\/000051228.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"863_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000338236","volume":"33","author":"RS Doody","year":"2012","unstructured":"Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J: Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer\u2019s disease: a subgroup analysis in patients already taking or not taking concomitant memantine. Dement Geriatr Cogn Disord. 2012, 33: 164-173. 10.1159\/000338236.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"863_CR13","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1177\/1533317512454708","volume":"27","author":"S Salloway","year":"2012","unstructured":"Salloway S, Mintzer J, Cummings JL, Geldmacher D, Sun Y, Yardley J, Mackell J: Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer\u2019s disease. Am J Alzheimers Dis Other Demen. 2012, 27: 421-432. 10.1177\/1533317512454708.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"863_CR14","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1001\/archneurol.2011.3758","volume":"69","author":"C Bernick","year":"2012","unstructured":"Bernick C, Cummings J, Raman R, Sun X, Aisen P: Age and rate of cognitive decline in Alzheimer disease: implications for clinical trials. Arch Neurol. 2012, 69: 901-905. 10.1001\/archneurol.2011.3758.","journal-title":"Arch Neurol"},{"key":"863_CR15","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1097\/00001756-200210070-00028","volume":"13","author":"GJ Ho","year":"2002","unstructured":"Ho GJ, Hansen LA, Alford MF, Foster K, Salmon DP, Galasko D, Thal LJ, Masliah E: Age at onset is associated with disease severity in Lewy body variant and Alzheimer\u2019s disease. NeuroReport. 2002, 13: 1825-1828. 10.1097\/00001756-200210070-00028.","journal-title":"NeuroReport"},{"key":"863_CR16","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1001\/archneur.58.8.1243","volume":"58","author":"D Mungas","year":"2001","unstructured":"Mungas D, Reed BR, Ellis WG, Jagust WJ: The effects of age on rate of progression of Alzheimer disease and dementia with associated cerebrovascular disease. Arch Neurol. 2001, 58: 1243-1247. 10.1001\/archneur.58.8.1243.","journal-title":"Arch Neurol"},{"key":"863_CR17","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1017\/S0033291709005492","volume":"39","author":"AE Van der Vlies","year":"2009","unstructured":"Van der Vlies AE, Koedam EL, Pijnenburg YA, Twisk JW, Scheltens P, Van der Flier WM: Most rapid cognitive decline in APOE epsilon4 negative Alzheimer\u2019s disease with early onset. Psychol Med. 2009, 39: 1907-1911. 10.1017\/S0033291709005492.","journal-title":"Psychol Med"},{"key":"863_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/jnnp.65.1.103","volume":"65","author":"GB Frisoni","year":"1998","unstructured":"Frisoni GB, Manfredi M, Geroldi C, Binetti G, Zanetti O, Bianchetti A, Trabucchi M: The prevalence of apoE-epsilon4 in Alzheimer\u2019s disease is age dependent. J Neurol Neurosurg Psychiatry. 1998, 65: 103-106. 10.1136\/jnnp.65.1.103.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"863_CR19","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jalz.2009.12.003","volume":"6","author":"DC Whitehair","year":"2010","unstructured":"Whitehair DC, Sherzai A, Emond J, Raman R, Aisen PS, Petersen RC, Fleisher AS: Influence of apolipoprotein E varepsilon4 on rates of cognitive and functional decline in mild cognitive impairment. Alzheimers Dement. 2010, 6: 412-419. 10.1016\/j.jalz.2009.12.003.","journal-title":"Alzheimers Dement"},{"key":"863_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2377-11-57","volume":"11","author":"M Farlow","year":"2011","unstructured":"Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A: Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer\u2019s disease. BMC Neurol. 2011, 11: 57-10.1186\/1471-2377-11-57.","journal-title":"BMC Neurol"},{"key":"863_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001\/jama.291.3.317.","journal-title":"JAMA"},{"key":"863_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2377-11-21","volume":"11","author":"M Sabbagh","year":"2011","unstructured":"Sabbagh M, Cummings J: Progressive cholinergic decline in Alzheimer\u2019s Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol. 2011, 11: 21-10.1186\/1471-2377-11-21.","journal-title":"BMC Neurol"},{"key":"863_CR23","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H","volume":"48","author":"DE Kuhl","year":"2000","unstructured":"Kuhl DE, Minoshima S, Frey KA, Foster NL, Kilbourn MR, Koeppe RA: Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex. Ann Neurol. 2000, 48: 391-395. 10.1002\/1531-8249(200009)48:3<391::AID-ANA17>3.0.CO;2-H.","journal-title":"Ann Neurol"},{"key":"863_CR24","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/00004714-200212000-00012","volume":"22","author":"V Kaasinen","year":"2002","unstructured":"Kaasinen V, Nagren K, Jarvenpaa T, Roivainen A, Yu M, Oikonen V, Kurki T, Rinne JO: Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer\u2019s disease. J Clin Psychopharmacol. 2002, 22: 615-620. 10.1097\/00004714-200212000-00012.","journal-title":"J Clin Psychopharmacol"},{"key":"863_CR25","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1001\/jama.281.15.1401","volume":"281","author":"KL Davis","year":"1999","unstructured":"Davis KL, Mohs RC, Marin D, Purohit DP, Perl DP, Lantz M, Austin G, Haroutunian V: Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA. 1999, 281: 1401-1406. 10.1001\/jama.281.15.1401.","journal-title":"JAMA"}],"container-title":["BMC Geriatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2318-13-56.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2318-13-56\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2318-13-56","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T14:56:44Z","timestamp":1468249004000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcgeriatr.biomedcentral.com\/articles\/10.1186\/1471-2318-13-56"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,6]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1186\/1471-2318-13-56","relation":{},"ISSN":["1471-2318"],"issn-type":[{"value":"1471-2318","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,6]]},"article-number":"56"}}